| Literature DB >> 32435394 |
Matteo Borgini1, Claudio Zamperini1,2, Federica Poggialini1, Luca Ferrante3, Vincenzo Summa4, Maurizio Botta1,2,5, Romano Di Fabio3,4.
Abstract
The marine natural product Largazole is the most potent Class I HDAC inhibitor identified to date. Since its discovery, many research groups have been attracted by the structural complexity and the peculiar anticancer activity, due to its capability to discriminate between tumor cells and normal cells. Herein, we discuss the synthesis and the in vitro biological profile of hybrid analogues of Largazole, as dual HDAC inhibitor and nitric oxide (NO) donors, potentially useful as anticancer agents. In particular, the metabolic stability of the modified thioester moiety of Largazole, bearing the NO-donor function/s, the in vitro release of NO, and the antiproliferative activity in tumor cell lines are presented.Entities:
Year: 2020 PMID: 32435394 PMCID: PMC7236235 DOI: 10.1021/acsmedchemlett.9b00643
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345